Create Free Account

By creating account you will get access to hot stocks & personalised emails

Anatara Lifesciences Ltd

Healthcare AU ANR

0.055AUD
0.01(30.95%)

Last update at 2025-02-20T02:15:00Z

Day Range

0.040.06
LowHigh

52 Week Range

0.020.07
LowHigh

Fundamentals

  • Previous Close 0.04
  • Market Cap11.74M
  • Volume76612
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-1.45666M
  • Revenue TTM-0.12318M
  • Revenue Per Share TTM-0.001
  • Gross Profit TTM -0.74891M
  • Diluted EPS TTM-0.01

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -2.02319M -2.53229M -1.99587M -3.36464M -2.86827M
Minority interest - - - - -
Net income -2.02319M -2.53561M -3.10420M -3.31258M -1.84820M
Selling general administrative 0.89M 1.38M 1.62M 2.06M 2.51M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.66M
Reconciled depreciation 0.02M 0.02M 0.00626M 0.02M 0.02M
Ebit -2.02082M -2.52897M -1.99557M -4.20592M -3.88835M
Ebitda -1.99605M -2.50430M -1.98931M -4.18982M -3.86562M
Depreciation and amortization 0.02M 0.02M 0.00626M 0.02M 0.02M
Non operating income net other - - - - -
Operating income -2.02082M -2.52897M -1.99557M -4.20592M -3.88835M
Other operating expenses 3.28M 3.02M 3.11M 4.21M 4.55M
Interest expense 0.00237M 0.00332M 0.00030M 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.02M 0.00600M 0.00912M 0.05M 0.14M
Net interest income 0.02M 0.00268M 0.00882M 0.05M 0.14M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.25M 0.00332M 1.11M -0.05206M -1.02007M
Total revenue - 0.00000M 0.00000M 0.00000M 0.66M
Total operating expenses 3.28M 3.02M 3.11M 4.21M 4.55M
Cost of revenue - - - - 0.78M
Total other income expense net 1.25M -0.00332M -0.00030M 0.84M 1.02M
Discontinued operations - - - - -
Net income from continuing ops -2.02319M -2.53229M -1.99587M -3.36464M -2.86827M
Net income applicable to common shares -2.02319M -2.53229M -1.99587M -3.36464M -2.86827M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 1.67M 1.42M 1.77M 4.33M 3.34M
Intangible assets - - - - 0.00000M
Earning assets - - - - -
Other current assets 0.02M 0.01M 0.02M 0.04M 0.02M
Total liab 0.31M 0.49M 0.40M 0.50M 0.49M
Total stockholder equity 1.36M 0.92M 1.36M 3.83M 2.86M
Deferred long term liab - - - - -
Other current liab 0.06M 0.42M 0.21M 0.21M 0.43M
Common stock 23.18M 21.37M 19.91M 19.76M 17.04M
Capital stock - 21.37M 19.91M 19.76M 17.04M
Retained earnings -22.09007M -20.79188M -18.98366M -16.60401M -14.73627M
Other liab - 0.00067M 0.00008M 0.03M 0.02M
Good will - - - - -
Other assets - - - - -
Cash 0.93M 0.35M 1.12M 3.43M 2.68M
Cash and equivalents - - - - -
Total current liabilities 0.30M 0.49M 0.36M 0.40M 0.46M
Current deferred revenue - - -0.02066M -0.01412M -0.01412M
Net debt -0.93202M -0.35118M -1.05440M -3.35216M -2.68237M
Short term debt - 0.00000M 0.02M 0.01M 0.01M
Short long term debt - - - - -
Short long term debt total - - 0.07M 0.08M 0.08M
Other stockholder equity - -0.57684M -0.92482M -3.15163M -2.30332M
Property plant equipment - 0.00326M 0.07M 0.09M 0.00719M
Total current assets 1.67M 1.42M 1.70M 4.24M 3.34M
Long term investments - - - - -
Net tangible assets - 0.92M 1.36M 3.83M 2.86M
Short term investments 0.05M 0.05M 0.05M 0.05M 0.00000M
Net receivables 0.67M 1.00M 0.51M 0.77M 0.63M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.25M 0.08M 0.15M 0.20M 0.03M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.28M 0.35M 0.44M 0.68M 0.55M
Additional paid in capital - - - - -
Common stock total equity - - - - 17.04M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00000M -0.00326M -0.06692M -0.08503M -0.00719M
Deferred long term asset charges - - - - -
Non current assets total 0.00079M 0.00326M 0.07M 0.09M 0.00719M
Capital lease obligations - - 0.07M 0.08M -
Long term debt total - 0.00000M 0.05M 0.07M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.00173M -0.05000M -0.00398M 4.05M 2.15M
Change to liabilities 0.17M -0.03351M -0.07691M 0.05M -0.05496M
Total cashflows from investing activities -0.00173M -0.05656M -0.00398M 4.05M 2.15M
Net borrowings -0.01819M -0.01744M -0.00051M -0.00051M -0.00051M
Total cash from financing activities 1.49M -0.02244M 2.85M 2.85M 2.85M
Change to operating activities -0.00793M -0.03057M -0.00668M 0.00473M -0.67780M
Net income -2.02319M -2.53229M -1.99587M -3.36464M -1.84820M
Change in cash -0.76902M -2.31187M 0.75M 1.32M -0.08765M
Begin period cash flow 1.12M 3.43M 2.68M 1.36M 1.45M
End period cash flow 0.35M 1.12M 3.43M 2.68M 1.36M
Total cash from operating activities -2.25790M -2.23288M -2.09748M -2.72490M -2.23766M
Issuance of capital stock 1.70M - 3.03M - -
Depreciation 0.02M 0.02M 0.00626M 0.02M 0.02M
Other cashflows from investing activities 0.00000M -0.05000M 0.00000M 4.05M 2.15M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.49555M 0.26M -0.14223M 0.27M 1.14M
Sale purchase of stock -0.18868M -0.00500M -0.18069M -0.18069M -
Other cashflows from financing activities -0.01819M -0.01744M -0.00051M 4.05M 2.34M
Change to netincome 0.07M 0.07M 0.12M 0.31M 0.20M
Capital expenditures 0.00173M 0.00656M 0.00398M 0.00408M 0.00408M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.49555M 0.26M -0.14223M 0.27M 1.49M
Stock based compensation 0.05M 0.07M 0.12M 0.31M -
Other non cash items -0.25947M 0.27M -0.10787M 0.62M 2.85M
Free cash flow -2.25962M -2.23944M -2.10146M -2.72898M -0.00408M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ANR
Anatara Lifesciences Ltd		 0.01 30.95% 0.06 - - 6.31 8.60 2.18 -1.018
CSL
CSL Ltd		 -5.96 2.25% 258.89 30.13 40.82 8.22 4.39 6.26 19.43
TLX
Telix Pharmaceuticals Ltd		 -0.36 1.34% 26.46 188.00 77.52 15.59 20.67 12.96 113.13
MSB
Mesoblast Ltd		 -0.04 1.43% 2.75 - 454.55 596.46 4.71 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.37 2.76% 13.04 13.16 35.21 8.77 5.06 6.36 8.29

Reports Covered

Stock Research & News

View All

Profile

Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. The company offers Gastrointestinal ReProgramming, a proprietary formulation to address irritable bowel syndrome. It also provides Detach for the treatment of diarrhea disease in piglets. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia.

Anatara Lifesciences Ltd

81 Flinders Street, Adelaide, SA, Australia, 5000

Key Executives

Name Title Year Born
Dr. David Lionel Brookes FACRRM, FAICD, MBBS Exec. Chairman 1960
Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D. Chief Operations Officer NA
Jane Lowe Managing Director of IR Department NA
Mr. Simon Erskine Chief Devel. Officer NA
Dr. Stephen Denaro AGIA, BCom, CA, GradDipApp CG, MAICD Company Sec. NA
Ms. Hayley van der Meer B Biomed Sc, Grad Dip Marketing Management Commercial Mang. NA
Dr. David Lionel Brookes F.A.C.I.D., FACRRM, FAICD, MBBS Executive Chairman 1960
Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D. COO & Executive Director NA
Mr. Simon Erskine Chief Development Officer NA
Dr. Stephen Denaro AGIA, BCom, CA, GradDipApp CG, MAICD Company Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

Market Research
ISO Certified pcidss

Kalkine Solutions Private Limited, an authorized representative of Kalkine Pty Ltd, holds the ISO 27001:2022 certification (Certificate No. IC-IS-2404072) and the PCI-DSS Version 4.0 Level 1 certification (Certificate No. CSNL1PCI8067).

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2025 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.